Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine.
about
Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signalingStress hormone exposure reduces mGluR5 expression in the nucleus accumbens: functional implications for interoceptive sensitivity to alcohol.Development of allosteric modulators of GPCRs for treatment of CNS disordersmGluR5 positive allosteric modulation and its effects on MK-801 induced set-shifting impairments in a rat operant delayed matching/non-matching-to-sample taskDouble Dissociation of the Roles of Metabotropic Glutamate Receptor 5 and Oxytocin Receptor in Discrete Social Behaviors.NMDA hypofunction as a convergence point for progression and symptoms of schizophreniaAutism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses.Leading compounds for the validation of animal models of psychopathology.Postnatal Phencyclidine (PCP) as a Neurodevelopmental Animal Model of Schizophrenia Pathophysiology and Symptomatology: A Review.Altering the course of schizophrenia: progress and perspectives.Neural changes induced by antipsychotic administration in adolescence: A review of studies in laboratory rodents.Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats.Role of mGlu5 Receptors and Inhibitory Neurotransmission in M1 Dependent Muscarinic LTD in the Prefrontal Cortex: Implications in Schizophrenia.Dissociable effects of mGluR5 allosteric modulation on distinct forms of impulsivity in rats: interaction with NMDA receptor antagonism.
P2860
Q27023967-7B0517B9-BFF3-4C02-ABB2-3B0C995BB941Q34068897-E46D97FF-90AC-48FF-8E97-4BA6C0F29F94Q34373958-9B4306F8-53FC-4035-BA22-C37D0E4AA1A6Q34785084-0357E26C-E1E2-4DA6-A767-F77938982812Q35960336-9283C195-EBBE-4751-A731-894696B848F9Q36718684-B3E1E6B1-8841-4875-A2A3-C454DC1D0891Q37068738-3482C8E9-7820-4683-9FB9-94BE3AFE2D49Q38128733-56AA1314-54EA-46D8-ACB0-A2A8BE848FF7Q38618630-A6FCD5D4-DC18-4B43-8D9A-539225183ED3Q38759421-110EB853-0788-4A55-BE7C-CD51B5DB740BQ38842111-551C69C9-AA7D-471D-9217-52EC89A6D103Q39284158-20239775-EB9D-4534-A7FB-8CCBB96004D4Q46168221-39571A32-801C-4012-B7C5-59DAA7A45586Q47836225-8A48C44B-8048-45CF-965B-A38BF084EF9BQ53471175-1E4215E6-D794-4654-8182-0864E64BE6A5
P2860
Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Enhancement of social novelty ...... treatment with phencyclidine.
@en
Enhancement of social novelty ...... treatment with phencyclidine.
@nl
type
label
Enhancement of social novelty ...... treatment with phencyclidine.
@en
Enhancement of social novelty ...... treatment with phencyclidine.
@nl
prefLabel
Enhancement of social novelty ...... treatment with phencyclidine.
@en
Enhancement of social novelty ...... treatment with phencyclidine.
@nl
P2093
P2860
P1433
P1476
Enhancement of social novelty ...... treatment with phencyclidine.
@en
P2093
Florence Loiseau
Mark J Millan
Nadège Morisot
Sylvie Girardon
P2860
P2888
P304
P356
10.1007/S00213-012-2845-3
P577
2012-09-16T00:00:00Z